

Therapeutic Drug Monitoring

Technologies, Companies & Markets

By

**Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland**

November 2021

A Jain PharmaBiotech Report

AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 172 articles out of a total of 1250 articles by 450 authors. These articles are updated on a yearly basis. Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2020) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

November 2021
Copyright © 2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold, or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	10
1. Introduction	12
Definitions	12
Historical Landmarks in the development of TDM	12
Pharmacology relevant to TDM	13
Pharmacokinetics	13
Pharmacodynamics	14
Pharmacogenetics	14
Pharmacogenomics	14
Pharmacoproteomics	14
Drug receptors	14
Protein binding	15
Therapeutic range of a drug.....	15
Variables that affect TDM.....	15
Indications for TDM	16
Multidisciplinary nature of TDM	17
Role of TDM in personalized medicine.....	18
2. Technologies for TDM	20
Introduction	20
Sample preparation	20
Proteomic technologies	20
Mass spectrometry	20
<i>Liquid chromatography MS.....</i>	<i>20</i>
<i>Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry</i>	<i>21</i>
<i>Combining capillary electrophoresis with MS.....</i>	<i>21</i>
<i>Gas-liquid chromatography</i>	<i>21</i>
<i>Tissue imaging mass spectrometry.....</i>	<i>22</i>
<i>New trends in sample preparation</i>	<i>22</i>
<i>Pressure Cycling Technology</i>	<i>22</i>
Desorption electrospray ionization imaging	23
High Performance Liquid Chromatography (HPLC)	23
<i>Ultra performance LC</i>	<i>23</i>
Application of HPLC and MS for separation of drug molecules	24
TDM using dry blood spots	25
<i>Analysis of dried blood spots for drugs using DESI</i>	<i>25</i>
<i>Quantitative analysis of drugs in dried blood spot by paper spray MS</i>	<i>25</i>
TDM in sweat	26
Immunoassays	26
Enzyme-linked immunosorbent assay	26
Cloned Enzyme Donor Immunoassay.....	27
Enzyme Multiplied Immunoassay Technique	27
Fluorescence Polarization Immunoassay	27
Particle Enhanced Turbidimetric Inhibition Immunoassay	28
Radioimmunometric assays	28
Biosensors	28
Biochips & Microarrays	29
Introduction	29
Microchip capillary electrophoresis	30
Phototransistor biochip biosensor	30
Microchip-based fluorescence polarization immunoassay for TDM.....	30
Cellular microarrays	30
Microfluidics for TDM	31
<i>Lab-on-a-chip.....</i>	<i>31</i>
<i>Micronics' microfluidic technology.....</i>	<i>31</i>
<i>Rheonix CARD technology.....</i>	<i>31</i>
<i>Nano-interface in a microfluidic chip.....</i>	<i>32</i>
<i>Levitation of nanofluidic drops with physical forces.....</i>	<i>32</i>
Nanoarrays	33
Nanobiotechnology	33
NanoDx™	33
Biomarkers	34
Applications of biomarkers in drug safety studies	34
Genomic technologies for toxicology biomarkers	35
Proteomic technologies for toxicology biomarkers	35
Metabonomic technologies for toxicology biomarkers.....	35

Integration of genomic and metabonomic data to develop toxicity biomarkers	36
Toxicology studies based on biomarkers	36
<i>Biomarkers of hepatotoxicity</i>	37
<i>Biomarkers of nephrotoxicity</i>	38
<i>Cardiotoxicity</i>	40
<i>Neurotoxicity</i>	40
Biomarkers in clinical trials	41
Molecular diagnostics	41
Novel technologies for TDM at point-of-care	42
NanoEye	42
Nanobiosensors	43
3. Drug Monitoring Instruments	44
Introduction	44
Description of important instruments	44
Abbott instruments	44
ARCHITECT c16000	44
ARCHITECT c4000	45
ARCHITECT c8000	45
ARCHITECT ci16200 Integrated System	45
ARCHITECT ci4100 Integrated System	46
ARCHITECT ci8200 integrated with the ARCHITECT i2000SR	46
ARCHITECT i1000SR	46
ARCHITECT i4000SR	47
AxSYM	47
Agilent's 6400 Series Triple Quadrupole LC/MS	48
Alfa Wassermann's ACE Alera	48
AMS Diagnostics' LIASYS	48
Beckman Coulter instruments	48
Beckman Coulter Unicel Series	48
AU5800 automated chemistry systems	49
AU480	49
Binding Site ESP600	50
bioMérieux Mini Vidas	50
Carolina BioLis 24i	50
Chromsystems' HPLC instruments	51
Grifols Triturus	51
ABX Pentra 400	51
Medica EasyRA	52
Nova Biomedical Critical Care Xpress	52
Ortho Clinical Diagnostics' VITROS® family of systems	52
Immunodiagnostic systems	53
Randox instruments	53
Randox RX Imola	53
Roche instruments	54
Cobas® 8000	54
COBAS INTEGRA® Systems	54
SCIEX instruments	54
SCIEX LC/MS/MS	54
Siemens instruments	55
ADVIA 1200	55
ADVIA Centaur XP immunoassay system	55
CLINITEK® AUWi System	55
Dimension® Xpand® Plus Integrated Chemistry System	55
EMIT® II Plus Syva®	56
Viva® Drug Testing Systems	56
Thermo Scientific instruments	56
Indiko	56
Tosoh AIA-Series	57
4. Applications of TDM	58
Introduction	58
Pharmaceutical research and drug development	58
Clinical trials	58
Computerized clinical decision support systems for TDM and dosing	58
Medication-related interferences with measurements of catecholamines	59
Polymorphisms of genes affecting drug metabolism	59
TDM for drug safety	59
TDM in special groups	60
The aged	60
Children	60

Pregnancy.....	60
TDM of prophylactic therapy	61
Monitoring of vitamin D levels	61
Monitoring of RBC folic acid levels during pregnancy	61
Applications according to various conditions	61
Anesthesia and critical care	61
<i>Optimizing antimicrobial dosing for critically ill patients</i>	<i>62</i>
<i>TDM monitoring of thiopental continuous infusion in critical care</i>	<i>62</i>
<i>Role of TDM in critical care cardiac patients.</i>	<i>63</i>
Cancer.....	63
Epilepsy.....	64
<i>Personalized approach to use of AEDs.....</i>	<i>64</i>
Infections	65
<i>Virus infections.....</i>	<i>65</i>
<i>Fungal infections.....</i>	<i>65</i>
Pain management	66
<i>Role of TDM in pain management.....</i>	<i>66</i>
<i>Monitoring of analgesic drugs in urine samples</i>	<i>66</i>
<i>AEDs as analgesics.....</i>	<i>67</i>
<i>Triptans for migraine</i>	<i>67</i>
Psychiatric disorders.....	67
<i>Guidelines for use of TDM in psychiatric patients.....</i>	<i>67</i>
<i>TDM of psychotropic drugs</i>	<i>69</i>
Emergency toxicology.....	69
Future of TDM	70

5. Drugs Requiring Monitoring	72
Introduction	72
Anticoagulants.....	73
<i>Dabigatran.....</i>	<i>74</i>
Analgesics	74
Monitoring of opioid use.....	74
<i>TDM of morphine</i>	<i>75</i>
<i>TDM of oxycodone.....</i>	<i>75</i>
<i>TDM of codeine.....</i>	<i>76</i>
Antiepileptics.....	76
Carbamazepine.....	77
<i>TDM of carbamazepine</i>	<i>77</i>
Gabapentin	78
Lacosamide.....	78
Lamotrigine.....	78
<i>TDM of lamotrigine.....</i>	<i>79</i>
Levetiracetam	80
<i>TDM of levetiracetam</i>	<i>80</i>
Phenobarbital	81
<i>TDM of phenobarbital</i>	<i>81</i>
Phenytoin	81
<i>TDM of phenytoin.....</i>	<i>82</i>
Primidone	83
<i>TDM of primidone.....</i>	<i>83</i>
Topiramate	83
<i>TDM of topiramate</i>	<i>84</i>
Valproic acid.....	84
<i>TDM of valproic acid</i>	<i>84</i>
TDM of multiple antiepileptic drugs in plasma/serum	85
Antiinflammatory agents	87
Infliximab	87
Antimicrobials.....	87
Antibiotics.....	87
<i>Amikacin.....</i>	<i>87</i>
<i>Anti-tuberculosis drugs.....</i>	<i>88</i>
<i>Chloramphenicol.....</i>	<i>88</i>
<i>Gentamicin.....</i>	<i>88</i>
<i>Tobramycin</i>	<i>89</i>
<i>Vancomycin.....</i>	<i>89</i>
<i>Norvancomycin.....</i>	<i>89</i>
Antiviral agents	90
<i>Anti-HIV drugs.....</i>	<i>90</i>
Antifungal agents.....	90
<i>Voriconazole.....</i>	<i>90</i>
Antidepressants.....	91

TDM of selective serotonin reuptake inhibitors	91
<i>Citalopram</i>	92
Antipsychotics	92
Aripiprazole.....	93
Clozapine.....	93
Quetiapine	93
Risperidone	94
TDM of AEDs in psychiatric disorders	95
TDM of lithium in psychiatric disorders.....	95
TDM of multiple drugs in psychiatry	95
Bronchodilators	95
Theophylline.....	95
Cardiovascular drugs	96
Antiarrhythmic drugs.....	96
Antihypertensive drugs	96
<i>β-blockers</i>	96
Cardiotonic drugs.....	96
<i>Digoxin</i>	96
TDM of statins for hypercholesterolemia	97
Chemotherapy for cancer	97
TDM of 5-FU.....	97
TDM of imitaniib	98
TDM of Methotrexate	98
TDM of paclitaxel	98
Drugs used for treatment of Alzheimer disease	99
Donepezil.....	99
Galantamine.....	99
Memantine	99
Drugs used for treatment of Parkinson disease	100
Monitoring of levodopa and carbidopa therapy	100
Catechol-O-methyltransferase inhibitors	101
Drugs for treatment of attention-deficit hyperactivity disorder	101
Atomoxetine.....	101
Methylphenidate	102
Hypnotic-sedative drugs	102
Benzodiazepines	102
Propofol.....	103
Immunosuppressive drugs	103
Immunosuppressants used for the treatment of various diseases.....	103
<i>Azathioprine</i>	103
<i>Hydroxychloroquine for patients with systemic lupus erythematosus</i>	104
<i>Methotrexate for rheumatoid arthritis</i>	104
<i>Mycophenolic acid for the treatment of lupus nephritis</i>	104
Immunosuppressants used for prevention of organ rejection in transplantation	104
<i>TDM of Tacrolimus in transplantation</i>	105
<i>TDM of cyclosporine A in transplantation</i>	106
<i>Monitoring of immunosuppression with mycophenolate mofetil</i>	106
Steroids	106
Prednisone	106
Miscellaneous drugs	107
Nimodipine.....	107
Sildenafil	108
6. Monitoring of Biological Therapies	110
Introduction	110
Cell therapy	110
In vivo tracking of cells.....	110
<i>Molecular imaging for tracking cells</i>	110
<i>MRI technologies for tracking cells</i>	111
<i>Superparamagnetic iron oxide nanoparticles as MRI contrast agents</i>	112
<i>Visualization of gene expression in vivo by MRI</i>	112
Gene therapy	113
Application of molecular diagnostic methods in gene therapy	113
Use of PCR to study biodistribution of gene therapy vector	113
PCR for verification of the transcription of DNA	114
In situ PCR for direct quantification of gene transfer into cells	114
Detection of retroviruses by reverse transcriptase (RT)-PCR.....	114
Confirmation of viral vector integration	114
Monitoring of gene expression	114
<i>Monitoring of gene expression by green fluorescent protein</i>	115
<i>Monitoring in vivo gene expression by molecular imaging</i>	115

Monoclonal antibodies	116
Natalizumab	116
7. Monitoring of Drug Abuse	118
Introduction	118
Tests used for detection of drug abuse	119
Forensic applications of detection of illicit drugs in fingerprints by MALDI MS	119
MS for doping control	120
Randox assays for DoA	120
Drugs of Abuse Array V	120
Urine drug testing	121
TDM of drugs for treatment of substance abuse-related disorders	121
Drug testing to monitor treatment of drug abuse	121
Minimum requirement for drug testing in patients	122
Analgesic abuse	122
Fentanyl abuse	122
B-blockers as doping agents	123
Detection of β -blockers in urine	123
Chronic alcohol abuse	123
Cocaine	124
CEDIA for cocaine in human serum	124
Detection of cocaine molecules by nanoparticle-labeled aptasensors	124
Infrared spectroscopy for detection of cocaine in saliva	124
Marijuana	125
Use of marijuana and synthetic cannabinoids	125
Detection of cannabinoids	126
<i>ELISA for detection of synthetic cannabinoids</i>	<i>126</i>
<i>Fluorescence spectral fingerprinting of synthetic cannabinoids</i>	<i>126</i>
Drug abuse for performance enhancement in sports	127
Historical aspects of drug abuse in sports	127
Drugs used by athletes for performance enhancement	128
Techniques used for detection of drug abuse by athletes	129
<i>Mass spectrometry for detection of peptide hormones</i>	<i>129</i>
<i>miRNAs for the detection of erythropoiesis-stimulating agents</i>	<i>129</i>
<i>Detection of anabolic steroids</i>	<i>130</i>
Body fluids and tissues used for detection of drug abuse in sports	130
<i>Urine drug testing</i>	<i>130</i>
<i>Spray (sweat) drug test kits</i>	<i>130</i>
<i>Hair drug testing</i>	<i>131</i>
Gene doping in sports	131
<i>Gene transfer methods used for enhancing physical performance</i>	<i>131</i>
<i>Misuse of cell therapy in sport</i>	<i>133</i>
<i>Challenges of detecting genetic manipulations in athletes</i>	<i>133</i>
Drug abuse testing in race horses	134
Limitations and future	135
Role of pharmaceutical industry in anti-doping testing	135
8. Markets for TDM	138
Introduction	138
Methods for market estimation and future forecasts	138
Global markets for TDM tests	138
Global markets for TDM according to technologies	139
Global TDM markets according to drug categories	139
<i>Agents used for treatment of Alzheimer disease</i>	<i>140</i>
<i>Analgesics</i>	<i>140</i>
<i>Anticancer agents</i>	<i>140</i>
<i>Anticoagulants</i>	<i>140</i>
<i>Antidepressants</i>	<i>141</i>
<i>Antiepileptics</i>	<i>141</i>
<i>Antimicrobials</i>	<i>141</i>
<i>Antipsychotics</i>	<i>141</i>
<i>Biological therapies</i>	<i>141</i>
<i>Bronchodilators</i>	<i>142</i>
<i>Cardiovascular drugs</i>	<i>142</i>
<i>Corticosteroids/antihistaminics/antiinflammatory agents</i>	<i>142</i>
<i>Hypnotic-sedatives</i>	<i>142</i>
<i>Immunosuppressants</i>	<i>142</i>
<i>Parkinson disease drugs</i>	<i>142</i>
Breakdown of global markets according to point of application of tests	142
Markets for TDM and DoA testing equipment	143
Geographical distribution of markets for TDM tests	143

Drivers for growth of TDM markets	144
Markets for DoA testing	145
Unmet needs in TDM	145
Cost-benefit studies	146
Simplifying assays and reducing time and cost	147
Strategies for developing markets	147
Physician education	148
Supporting research on TDM	148
Biomarker patents for drug monitoring	148
9. Companies	150
Profiles of companies	150
Collaborations	197
10. References	198

Tables

Table 1-1: Historical landmarks in the development of therapeutic drug monitoring	12
Table 4-1: Psychotropic drugs requiring TDM	68
Table 5-1: Drugs requiring TDM	72
Table 5-2: Indications and therapeutic ranges of various AEDs	77
Table 6-1: Molecular imaging methods for tracking cells in vivo	111
Table 6-2: Applications of molecular diagnostics in gene therapy	113
Table 7-1: Commonly tested drugs of abuse and recreational drugs	118
Table 7-2: Testing and confirmation cutoff concentrations/detection times for DoA	122
Table 7-3: Historical landmarks of drug abuse in sports	127
Table 7-4: Drugs used by athletes for performance enhancement	128
Table 7-5: Genes that may be used for performance enhancement	131
Table 8-1: Global markets for TDM according to technologies from 2020-2030	139
Table 8-2: Global markets for TDM according to tests in drug categories 2020-2030	139
Table 8-3: Global markets for TDM according to point of application 2020-2030	143
Table 8-4: Markets for TDM and DoA testing equipment 2020-2030	143
Table 8-5: Geographical distribution of markets for TDM tests 2020-2030	144
Table 8-6: Drivers for growth of TDM markets	144
Table 8-7: Global markets for DoA testing 2020-2030	145
Table 9-1: Major players in therapeutic drug monitoring	150
Table 9-2: Drugs for which monitoring and detection tests are provided by LabCorp	171
Table 9-3: Collaborations of companies involved in TDM	197

Figures

Figure 1-1: Therapeutic window of a drug	15
Figure 1-2: Therapeutic range of a drug	15
Figure 1-3: Flow chart of TDM	17
Figure 1-4: Interrelationships of TDM	17
Figure 2-1: Separation of structurally similar drug molecules by HPLC	24
Figure 2-2: Determination of the identity of a target substance by mass spectrometry	24
Figure 2-3: Basic principle of a biosensor	29
Figure 8-1: Unmet needs in TDM	146
Figure 8-2: Metabolism of azathioprine and biomarkers for TDM	149